Trial · NCT02682407
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
NCT02682407, Phase 2, Terminated, Omeros Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721. Trials, record NCT02682407. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02682407
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
- NCT number
- NCT02682407
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 31 participants, actual
- Lead sponsor
- Omeros Corporation
- Conditions
- IgAN, LN, MN, C3G
- Interventions
- OMS721 (narsoplimab)
- First posted
- 2016-02-15
- Last updated
- 2026-03-30
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy Participants With Treatment Related Adverse Events (AE). | up to 104 weeks | Proportion of participants with Treatment Related Adverse Events (AE). |
| Primary | Cohort 4: Proportion of IgAN Participants of Asian Descent With Treatment Related AEs. | 38 weeks | Proportion of participants with Treatment Related Adverse Events (AE). |
| Primary | Cohort 4: Change From Baseline in Serum and Urine Complement Component Levels. | 38 weeks | Concentrations of urine complement components |
| Secondary | Cohort 1-3: Absolute Change From Baseline in Serum Narsoplimab Concentrations (ng/mL). | up to 104 weeks | Pharmacokinetics (PK): Maximum plasma concentrations (Cmax) |
| Secondary | Cohort 4: Change From Baseline in Serum Narsoplimab Concentrations. | 38 weeks | Pharmacokinetics (PK): Maximum plasma concentrations (Cmax) |
| Secondary | Cohort 1-3: Change From Baseline in Urine Protein Excretion (UPE) mg/24hrs. | up to 120 days | Change from Baseline in Urine Protein Excretion (UPE) in mg/24s up to Day 120 |
| Secondary | Cohort 1-3: Change From Baseline in Urine Albumin/Creatinine Ratio. | up to 104 weeks | Change From Baseline in Urine Albumin/Creatinine Ratio (mg/g) in OMS721 subjects at Day 120. Data was displayed for up to 120 days, because some patients received retreatment afterwards. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33163724 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02682407
GET https://conductscience.org/api/trials/v1/NCT02682407/registered